Guoqing Cao

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Phospholipid transfer protein is regulated by liver X receptors in vivo
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 277:39561-5. 2002
  2. ncbi request reprint Liver X receptors as potential therapeutic targets for multiple diseases
    Guoqing Cao
    Division of Cardiovascular Discovery, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug News Perspect 17:35-41. 2004
  3. ncbi request reprint Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates
    Jian Wang
    Cardiovascular Division, Lilly Research Labs, Eli Lilly and Company, DC 0343, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 332:735-42. 2005
  4. ncbi request reprint Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Alzheimer Res 4:179-84. 2007
  5. ncbi request reprint Identification and characterization of hamster stearoyl-CoA desaturase isoforms
    Jian Wang
    Cardiovascular and Diabetes Drug Discovery, Lilly Research Labs, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Lipids 43:197-205. 2008
  6. pmc Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 52:2169-76. 2011
  7. ncbi request reprint Glycerolipid acyltransferases in triglyceride metabolism and energy homeostasis-potential as drug targets
    Guoqing Cao
    Lilly Research Laboratories, 359 Merrill Street, Indianapolis, IN 46285, USA
    Endocr Metab Immune Disord Drug Targets 12:197-206. 2012
  8. ncbi request reprint Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease
    Guoqing Cao
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Endocr Metab Immune Disord Drug Targets 8:238-43. 2008
  9. ncbi request reprint Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 278:1131-6. 2003
  10. ncbi request reprint Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo
    Thomas P Beyer
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 309:861-8. 2004

Collaborators

Detail Information

Publications41

  1. ncbi request reprint Phospholipid transfer protein is regulated by liver X receptors in vivo
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 277:39561-5. 2002
    ..We conclude that PLTP is a direct target gene of LXRs in vivo and plays an important role in LXR agonist-mediated HDL cholesterol and size increase in mice...
  2. ncbi request reprint Liver X receptors as potential therapeutic targets for multiple diseases
    Guoqing Cao
    Division of Cardiovascular Discovery, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Drug News Perspect 17:35-41. 2004
    ..This review intends to summarize the most recent progress in the field and provide an assessment of LXRs as potential therapeutic targets...
  3. ncbi request reprint Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates
    Jian Wang
    Cardiovascular Division, Lilly Research Labs, Eli Lilly and Company, DC 0343, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 332:735-42. 2005
    ..These data suggested that hSCD5 plays a role distinct from that of hSCD1 during development and in normal physiological conditions...
  4. ncbi request reprint Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Alzheimer Res 4:179-84. 2007
    ..Taken together, these findings suggest that brain-penetrable LXR agonists or modulators may be useful therapeutic agents for the treatment and (or) prevention of Alzheimer's disease...
  5. ncbi request reprint Identification and characterization of hamster stearoyl-CoA desaturase isoforms
    Jian Wang
    Cardiovascular and Diabetes Drug Discovery, Lilly Research Labs, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Lipids 43:197-205. 2008
    ..Very low levels of hmSCD3 mRNA can be detected in the tissues tested. This report is the first description of three SCD isoforms in the hamster and will provide useful tools in the further study of fatty acids metabolism in this species...
  6. pmc Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 52:2169-76. 2011
    ..Our data indicate that evacetrapib is a potent and selective CETP inhibitor without torcetrapib-like off-target liabilities. Evacetrapib is currently in phase II clinical development...
  7. ncbi request reprint Glycerolipid acyltransferases in triglyceride metabolism and energy homeostasis-potential as drug targets
    Guoqing Cao
    Lilly Research Laboratories, 359 Merrill Street, Indianapolis, IN 46285, USA
    Endocr Metab Immune Disord Drug Targets 12:197-206. 2012
    ....
  8. ncbi request reprint Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease
    Guoqing Cao
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Endocr Metab Immune Disord Drug Targets 8:238-43. 2008
    ..We review here the current understanding of PCSK9 and its potential as a therapeutic target through which to reduce LDL cholesterol for prevention and treatment of coronary heart disease...
  9. ncbi request reprint Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis
    Guoqing Cao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 278:1131-6. 2003
    ..These data not only suggest that LXRs are novel targets for diabetes but also reveal an unanticipated role for these receptors, further linking lipid and glucose metabolism...
  10. ncbi request reprint Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo
    Thomas P Beyer
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 309:861-8. 2004
    ..Liver lipoprotein lipase expression was additively increased upon LXR agonist and PPARalpha agonist coadministration. Our studies mark the first exploration of nuclear receptor interplay on lipid homeostasis in vivo...
  11. ncbi request reprint Liver X receptors (LXRs) regulate apolipoprotein AIV-implications of the antiatherosclerotic effect of LXR agonists
    Yu Liang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Mol Endocrinol 18:2000-10. 2004
    ..In addition, we identified a functional LXR-responsive element at 3' end enhancer region of mouse ApoAIV gene. We conclude that ApoAIV is a direct target gene of LXRs that may contribute to the antiatherogenic effect of LXR activation...
  12. ncbi request reprint A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes
    Yu Liang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Neurochem 88:623-34. 2004
    ..LXR/RXR agonists may have significant impact on the pathogenesis of multiple neurological diseases, including AD...
  13. ncbi request reprint A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity
    Robert J Schmidt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 47:1037-44. 2006
    ..Our data thus provide a molecular basis for the hypocholesterolemic activity of the 15-ketosterol and further suggest its potential antiatherosclerotic benefit as an LXR agonist...
  14. ncbi request reprint Liver X receptor and retinoic X receptor mediated ABCA1 regulation and cholesterol efflux in macrophage cells-messenger RNA measured by branched DNA technology
    Youyan Zhang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Mol Genet Metab 77:150-8. 2002
    ....
  15. doi request reprint Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
    Robert J Schmidt
    Lilly Research Laboratories, Eli Lilly and Company, Cardiovascular Research, 355 Merrill Street, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 370:634-40. 2008
    ..Taken together, our studies indicate that secreted PCSK9 can potentially impact extrahepatic tissue cholesterol homeostasis by regulating extrahepatic tissue LDLR levels...
  16. ncbi request reprint Hepatic peroxisomal fatty acid beta-oxidation is regulated by liver X receptor alpha
    Tonghuan Hu
    Lilly Research Laboratories, Department of Cardiovascular Research, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    Endocrinology 146:5380-7. 2005
    ....
  17. doi request reprint Identification and characterization of a major liver lysophosphatidylcholine acyltransferase
    Yang Zhao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Biol Chem 283:8258-65. 2008
    ....
  18. ncbi request reprint A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor
    Jeffrey Thomas
    Department of Cardiovascular Research, Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Biol Chem 278:2403-10. 2003
    ..These findings provide not only an unexpected mechanism by which fenofibrate inhibits lipogenesis but also the basis for examination of the pharmacology of an LXR ligand in humans...
  19. ncbi request reprint Enlargement of high density lipoprotein in mice via liver X receptor activation requires apolipoprotein E and is abolished by cholesteryl ester transfer protein expression
    Xian Cheng Jiang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Biol Chem 278:49072-8. 2003
    ..Our studies provide direct evidence that apoE and CETP are intimately involved in the accumulation of the enlarged HDL (HDL1 or HDLc) particles in mice...
  20. doi request reprint Development of a quantitative biochemical and cellular sphingomyelin synthase assay using mass spectrometry
    Yanqun Chen
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Anal Biochem 438:61-6. 2013
    ..The establishment of quantitative biochemical and cellular SMS assays may help to facilitate the discovery of novel SMS1- or SMS2-specific inhibitors...
  21. ncbi request reprint Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
    Yue Wei Qian
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 48:1488-98. 2007
    ....
  22. doi request reprint Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation
    Yanqun Chen
    Department of Endocrine Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 415:515-8. 2011
    ..Furthermore, LDLR protein carrying mutations in the C-terminal ubiquitination sites was resistant to PCSK9-mediated degradation. Our data suggest that the ubiquitination system is involved in PCSK9-induced LDLR degradation...
  23. pmc The microsomal cardiolipin remodeling enzyme acyl-CoA lysocardiolipin acyltransferase is an acyltransferase of multiple anionic lysophospholipids
    Yang Zhao
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 50:945-56. 2009
    ..Our studies provide the molecular basis for future investigations of the physiological function of ALCAT1 and offer evidence of critical amino acids involved in substrate binding for the family of glycerolipid acyltransferases...
  24. pmc AGPAT6 is a novel microsomal glycerol-3-phosphate acyltransferase
    Yan Qun Chen
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Biol Chem 283:10048-57. 2008
    ..Our data indicate that AGPAT6 is a microsomal GPAT, and we propose renaming this enzyme GPAT4...
  25. ncbi request reprint An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma
    Jason S Troutt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 49:581-7. 2008
    ....
  26. pmc Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
    Jason S Troutt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 51:345-51. 2010
    ....
  27. doi request reprint Development of a novel sandwich ELISA for measuring cell lysate ABCA1 protein levels
    Jason S Troutt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Lipids 45:757-64. 2010
    ..Together, these results suggest that the sandwich ELISA may be a sensitive and effective method for quantitating ABCA1 protein levels...
  28. ncbi request reprint A novel splicing variant of proprotein convertase subtilisin/kexin type 9
    Robert J Schmidt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    DNA Cell Biol 27:183-9. 2008
    ..Both N425S and A443T mutants were processed normally, secreted, and reduced LDLR levels. However, the physiological function of this novel splicing variant of PCSK9 has yet to be determined...
  29. ncbi request reprint A natural product ligand of the oxysterol receptor, liver X receptor
    Kelli S Bramlett
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46060, USA
    J Pharmacol Exp Ther 307:291-6. 2003
    ....
  30. ncbi request reprint Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
    Holly E Careskey
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Lipid Res 49:394-8. 2008
    ..These results suggest that the addition of a PCSK9 inhibitor to statin therapy may result in even further LDL-C decreases...
  31. ncbi request reprint Genetic disorders associated with ATP binding cassette cholesterol transporters
    Thomas P Burris
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Mol Genet Metab 77:13-20. 2002
    ..This summary provides an overview and discussion of the most recent progress that includes molecular mechanism and regulation of cholesterol transport mediated by these ABC transporters...
  32. doi request reprint Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein
    Thomas P Beyer
    Cardiovascular Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Lipids 43:611-8. 2008
    ..We conclude that PPARalpha agonists upregulate CETP expression and activity and may play an important role in PPARalpha (agonist mediated HDL cholesterol homeostasis in humans...
  33. ncbi request reprint Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol
    William E Alborn
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Clin Chem 53:1814-9. 2007
    ..Relatively little is known about PCSK9 in human serum...
  34. pmc Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
    Robert J Konrad
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Lipids Health Dis 10:38. 2011
    ....
  35. doi request reprint The acyl coenzymeA:monoacylglycerol acyltransferase 3 (MGAT3) gene is a pseudogene in mice but encodes a functional enzyme in rats
    Yong Gang Yue
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Lipids 46:513-20. 2011
    ..Our results thus provide the molecular basis to understand the relative functional role of MGAT2 and MGAT3 and also for future exploration of MGAT3 function in animal models...
  36. ncbi request reprint Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A
    Youyan Zhang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 334:729-32. 2005
    ..Our results provided direct evidence indicating that HM74A, but not HM74, was sufficient to mediate anti-lipolytic effect of niacin in adipose tissue...
  37. pmc Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression
    Yue Li
    Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    Arterioscler Thromb Vasc Biol 33:1513-20. 2013
    ..Sphingomyelin synthase (SMS), using ceramide as one of the substrates to produce sphingomyelin, sits at the crossroads of sphingolipid biosynthesis. SMS has 2 isoforms: SMS1 and SMS2. SMS2 is the major isoform in liver...
  38. doi request reprint Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration
    Jason S Troutt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Clin Chem 58:1225-32. 2012
    ....
  39. doi request reprint Dual-monoclonal, sandwich immunoassay specific for glucose-dependent insulinotropic peptide1-42, the active form of the incretin hormone
    Jason S Troutt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Clin Chem 57:849-55. 2011
    ..There is currently no described monoclonal antibody-based sandwich immunoassay to quantify concentrations of GIP(1-42), the active form of the peptide...
  40. pmc Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization
    Zhiqiang Li
    Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, 450 Clarkson Ave Box 5, Brooklyn, NY 11203, USA
    Biochim Biophys Acta 1771:1186-94. 2007
    ....
  41. ncbi request reprint Adipose tissue-specific CETP expression in mice: impact on plasma lipoprotein metabolism
    Hongwen Zhou
    Department of Anatomy and Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    J Lipid Res 47:2011-9. 2006
    ..Moreover, adipose tissue CETP expression changes triglyceride and cholesterol content and the size of adipocytes...